Focused ultrasound is one of my favorite new experimental treatments for brain tumors. It can be used in many different ways. This webinar will focus (pun intended:) on using it for sonodynamic therapy, which is similar to photodynamic therapy but uses sound instead of light. A dye is administered to the patient, which collects mostly in the tumor cells. Then focused ultrasound is delivered to the brain, using an external device (no cutting, no bleeding). The ultrasound excites the dye molecules which kills the tumor cells and leaves the normal cells alone. That is the theory - this trial is testing to see if it really works. If it works out, this will be a major breakthrough in the treatment of tumors. This simple noninvasive procedure can be repeated when / if the tumor grows back to keep it at bay. I would hope that combining a few relatively non-toxic therapies might lead to the cure - in a way that doesn't torture the patient!
Posted on: 01/06/2023
Webinar on Focused Ultrasound for the treatment of brain tumors. Monday 1/9/23 at 7pm Eastern
We rescheduled this webinar (which was supposed to take place a few weeks ago) for Monday, Jan 9, 2023 at 7pm, Eastern time. The speaker is: Dr. Vijay Agarwal who is a tri-fellowship trained brain tumor surgeon and is a pioneer in complex brain tumor surgery. Vijay has published extensively and has three textbooks published or in-press based on his innovative work. He earned a BS from UCLA in Electrical Engineering with a Biomedical Engineering specialization. After medical school, he completed his neurosurgery residency at Duke University Medical Center, with one of the most renowned brain tumor centers in the world. Vijay has devoted his life to improving the lives of patients with brain cancer and has over 20 years in the medical device/biotechnology industry.
As always, our webinars are free to participate in, and no prior registration required. Just go to virtualtrials.org/webinar a few minutes before the webinar starts!
Click HERE to return to brain tumor news headlines.